Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 6 | 2023 | 152 | 3.090 |
Why?
|
| Breast Neoplasms | 14 | 2024 | 3000 | 2.940 |
Why?
|
| Receptor, ErbB-2 | 7 | 2024 | 245 | 2.610 |
Why?
|
| Neoadjuvant Therapy | 10 | 2024 | 373 | 2.530 |
Why?
|
| Mastectomy, Segmental | 2 | 2024 | 101 | 1.810 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1543 | 1.500 |
Why?
|
| Receptors, Progesterone | 2 | 2024 | 174 | 1.120 |
Why?
|
| Receptors, Estrogen | 2 | 2024 | 393 | 1.050 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 2001 | 0.890 |
Why?
|
| Genomics | 2 | 2024 | 761 | 0.810 |
Why?
|
| Immunoconjugates | 1 | 2022 | 110 | 0.800 |
Why?
|
| Precision Medicine | 2 | 2024 | 410 | 0.740 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 322 | 0.740 |
Why?
|
| Specimen Handling | 1 | 2021 | 102 | 0.740 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 16 | 0.740 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 35 | 0.730 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2024 | 1239 | 0.730 |
Why?
|
| Medical Oncology | 1 | 2024 | 382 | 0.700 |
Why?
|
| Prognosis | 7 | 2024 | 3773 | 0.700 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 296 | 0.680 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 94 | 0.670 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2019 | 21 | 0.660 |
Why?
|
| Pneumococcal Infections | 1 | 2019 | 47 | 0.650 |
Why?
|
| Neoplasms | 3 | 2024 | 3035 | 0.620 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1363 | 0.580 |
Why?
|
| Humans | 28 | 2024 | 89073 | 0.570 |
Why?
|
| Patient Selection | 1 | 2020 | 682 | 0.560 |
Why?
|
| Internal Medicine | 1 | 2020 | 355 | 0.550 |
Why?
|
| Female | 19 | 2024 | 46014 | 0.500 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1114 | 0.380 |
Why?
|
| Internship and Residency | 1 | 2020 | 1041 | 0.370 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 2412 | 0.370 |
Why?
|
| Machine Learning | 2 | 2024 | 257 | 0.360 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 273 | 0.350 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2022 | 132 | 0.340 |
Why?
|
| Middle Aged | 10 | 2024 | 25865 | 0.310 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 459 | 0.310 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 2347 | 0.290 |
Why?
|
| Immunotherapy | 2 | 2022 | 669 | 0.270 |
Why?
|
| Retrospective Studies | 5 | 2023 | 9003 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2024 | 485 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 2552 | 0.220 |
Why?
|
| Cohort Studies | 4 | 2023 | 2863 | 0.210 |
Why?
|
| Anthracyclines | 1 | 2022 | 38 | 0.210 |
Why?
|
| Hormones | 1 | 2022 | 139 | 0.200 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.190 |
Why?
|
| Contrast Media | 2 | 2023 | 1090 | 0.190 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.190 |
Why?
|
| Connecticut | 1 | 2020 | 26 | 0.180 |
Why?
|
| Shift Work Schedule | 1 | 2020 | 6 | 0.180 |
Why?
|
| Work Schedule Tolerance | 1 | 2020 | 37 | 0.180 |
Why?
|
| Aged | 5 | 2024 | 19078 | 0.180 |
Why?
|
| Software | 2 | 2024 | 665 | 0.180 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 89 | 0.180 |
Why?
|
| Automation | 1 | 2020 | 111 | 0.170 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1710 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2020 | 76 | 0.170 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 529 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 410 | 0.170 |
Why?
|
| United States | 3 | 2022 | 6957 | 0.170 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1214 | 0.170 |
Why?
|
| Algorithms | 2 | 2024 | 1875 | 0.170 |
Why?
|
| Tumor Burden | 1 | 2020 | 308 | 0.170 |
Why?
|
| Maxillary Sinus | 1 | 2019 | 26 | 0.170 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 1796 | 0.160 |
Why?
|
| Streptococcus pneumoniae | 1 | 2019 | 49 | 0.160 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 372 | 0.160 |
Why?
|
| Male | 5 | 2023 | 42254 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 261 | 0.160 |
Why?
|
| Carcinoma | 1 | 2022 | 443 | 0.160 |
Why?
|
| Mouth Neoplasms | 1 | 2020 | 198 | 0.160 |
Why?
|
| Age Factors | 1 | 2023 | 1867 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 848 | 0.150 |
Why?
|
| Bacteremia | 1 | 2019 | 102 | 0.150 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 3657 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1149 | 0.140 |
Why?
|
| Logistic Models | 1 | 2020 | 1212 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2020 | 548 | 0.140 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1429 | 0.130 |
Why?
|
| Adult | 5 | 2024 | 26508 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 3443 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2021 | 2291 | 0.110 |
Why?
|
| Mutation | 2 | 2023 | 4132 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2612 | 0.100 |
Why?
|
| Breast | 2 | 2023 | 292 | 0.090 |
Why?
|
| Risk Factors | 1 | 2021 | 5466 | 0.090 |
Why?
|
| Kinetics | 2 | 2023 | 1528 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2024 | 8203 | 0.070 |
Why?
|
| Computers | 1 | 2024 | 112 | 0.060 |
Why?
|
| Hydrodynamics | 1 | 2022 | 19 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 280 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 781 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 181 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2022 | 298 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 156 | 0.050 |
Why?
|
| Computational Biology | 1 | 2024 | 542 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2023 | 187 | 0.050 |
Why?
|
| Survival Rate | 1 | 2023 | 1889 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 2014 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 4273 | 0.030 |
Why?
|